Article Text

Download PDFPDF
Patients with atrial fibrillation and coronary events: are we any closer to coming out from the labyrinth of the various antithrombotic strategies?

Statistics from


  • Competing interests GP: speaker/consultant/advisory board for Amgen, Sanofi, Bayer, Boehringer-Ingelheim, BMS-Pfizer, Daiichi Sankyo, Astra Zeneca, Sigma-Tau, Malesci, PIAM and MSD.

  • Provenance and peer review Commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • Arrhythmias and sudden death
    Caroline Sindet-Pedersen Laila Staerk Morten Lamberts Thomas Alexander Gerds Jeffrey S Berger Anders Nissen Bonde Jannik Langtved Pallisgaard Morten Lock Hansen Christian Torp-Pedersen Gunnar H Gislason Jonas Bjerring Olesen